These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33929488)

  • 21. SARS-CoV-2 RNA and antibody detection in breast milk from a prospective multicentre study in Spain.
    Bäuerl C; Randazzo W; Sánchez G; Selma-Royo M; García Verdevio E; Martínez L; Parra-Llorca A; Lerin C; Fumadó V; Crovetto F; Crispi F; Pérez-Cano FJ; Rodríguez G; Ruiz-Redondo G; Campoy C; Martínez-Costa C; Collado MC;
    Arch Dis Child Fetal Neonatal Ed; 2022 Mar; 107(2):216-221. PubMed ID: 34417223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
    Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
    J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
    Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
    Front Immunol; 2022; 13():829665. PubMed ID: 35154152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases.
    Kharlamova N; Dunn N; Bedri SK; Jerling S; Almgren M; Faustini F; Gunnarsson I; Rönnelid J; Pullerits R; Gjertsson I; Lundberg K; Månberg A; Pin E; Nilsson P; Hober S; Fink K; Fogdell-Hahn A
    Front Immunol; 2021; 12():666114. PubMed ID: 34012450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study.
    Gebrecherkos T; Kiros YK; Challa F; Abdella S; Gebreegzabher A; Leta D; Desta A; Hailu A; Tasew G; Abdulkader M; Tessema M; Tollera G; Kifle T; Arefaine ZG; Schallig HH; Adams ER; Urban BC; de Wit TFR; Wolday D
    PLoS One; 2022; 17(3):e0263627. PubMed ID: 35320286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis.
    Piñar Morales R; Ramírez Rivas MA; Barrero Hernández FJ
    Neurologia (Engl Ed); 2021; 36(9):698-703. PubMed ID: 34103271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
    Bsteh G; Assar H; Hegen H; Heschl B; Leutmezer F; Di Pauli F; Gradl C; Traxler G; Zulehner G; Rommer P; Wipfler P; Guger M; Enzinger C; Berger T;
    PLoS One; 2021; 16(7):e0255316. PubMed ID: 34314457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study.
    Science M; Bolotin S; Silverman M; Nadarajah J; Maguire B; Parekh RS; McGeer A; Schwartz KL; Alexander L; Allen U; Ariyarajah A; Castellani L; Cohn RD; Downing M; Katz K; Kazmi K; Leis JA; Liu D; Pernica JM; Schneiderman JE; Sumaida M; Campigotto A
    CMAJ Open; 2021; 9(4):E929-E939. PubMed ID: 34642255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina.
    Cristiano E; Patrucco L; Rojas JI; Nuñez S
    Mult Scler Relat Disord; 2020 Sep; 44():102307. PubMed ID: 32563927
    [No Abstract]   [Full Text] [Related]  

  • 33. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
    Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.
    Capone F; Motolese F; Luce T; Rossi M; Magliozzi A; Di Lazzaro V
    Mult Scler Relat Disord; 2021 Feb; 48():102734. PubMed ID: 33429305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between viral load, infection-to-delivery interval and mother-to-child transfer of anti-SARS-CoV-2 antibodies.
    Poon LC; Leung BW; Ma T; Yu FNY; Kong CW; Lo TK; So PL; Leung WC; Shu W; Cheung KW; Moungmaithong S; Wang CC
    Ultrasound Obstet Gynecol; 2021 Jun; 57(6):974-978. PubMed ID: 33798280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.
    Berardis S; Verroken A; Vetillart A; Struyf C; Gilbert M; Gruson D; Gohy S
    J Cyst Fibros; 2020 Nov; 19(6):872-874. PubMed ID: 32828701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 antibody prevalence and correlates of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June-October 2020.
    Coyer L; Boyd A; Schinkel J; Agyemang C; Galenkamp H; Koopman ADM; Leenstra T; Moll van Charante EP; van den Born BH; Lok A; Verhoeff A; Zwinderman AH; Jurriaans S; van Vught LA; Stronks K; Prins M
    BMJ Open; 2022 Jan; 12(1):e052752. PubMed ID: 34992110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic.
    Meca-Lallana V; Aguirre C; Cardeñoso L; Alarcon T; Figuerola-Tejerina A; Del Río B; Álvarez MR; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102244. PubMed ID: 32544863
    [No Abstract]   [Full Text] [Related]  

  • 40. SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature.
    Saraceno L; Susani EL; Marazzi MR; Moioli MC; Agostoni EC; Protti A
    Neurol Sci; 2021 Dec; 42(12):4881-4884. PubMed ID: 34431013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.